Evidence map›Paper›PMID 42118277›Full record

SynthesisAbdominal radiology (New York)2026

Performance of MRI protocols for diagnosis of benign and malignant ovarian tumors: a systematic review and meta-analysis.

Pin Yang, Fengxian Fan, Tingli Yang, Rui Wang

Abstract readMeta-AnalysisSystematic ReviewReview
PubMed Publisher
In one paragraph

Synthesis in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pin YangDepartment of Magnetic Resonance, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, PR China.
Fengxian FanDepartment of Magnetic Resonance, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, PR China.
Tingli YangDepartment of Magnetic Resonance, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, PR China.
Rui WangDepartment of Intensive Care Unit, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, PR China. 727111682@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWith the continuous increase in the incidence of ovarian tumors in gynecology, the differential diagnosis of benign and malignant ovarian tumors is of great significance for subsequent treatment. The primary aim of this meta-analysis was to systematically evaluate the diagnostic value of MRI in differentiating benign from malignant ovarian tumors.

methodsA search was conducted in the PubMed and Web of Science databases to identify diagnostic tests for ovarian tumors using MRI, The search deadline is April 29, 2025. Two reviewers independently screened the literature, extracted data, and assessed the methodological quality of the included studies according to inclusion and exclusion criteria. Subsequently, a meta-analysis was performed using Stata 15.1 software.

resultsUltimately, 81 articles were included, encompassing 12,594 patients and 14,023 lesions. Based on the lesion analysis, the pooled sensitivity, pooled specificity, pooled positive likelihood ratio, pooled negative likelihood ratio, and diagnostic odds ratio for differentiating benign and malignant ovarian tumors by MRI were 0.92 (95% CI: 0.91-0.94), 0.88 (95% CI: 0.86-0.90), 7.9 (95% CI: 6.6-9.5), 0.09 (95% CI: 0.07-0.11), and 93 (95% CI: 69-125), respectively. The pooled area under the SROC curve was 0.96 (95% CI: 0.94-0.97). Of the 81 included studies, 13 reported diagnostic performance for DWI alone; these were analyzed as a distinct subgroup within the overall meta-analysis. Based on the lesion analysis, the pooled sensitivity, pooled specificity, diagnostic odds ratio, and area under the curve for differentiating benign and malignant ovarian tumors by DWI were 0.88 (95% CI: 0.83-0.92), 0.79 (95% CI: 0.72-0.84), 28 (95% CI: 17-47), and 0.90 (95% CI: 0.87-0.92), respectively. For using MR scoring system (36 studies), pooled sensitivity was 0.94 (95% CI: 0.92-0.96) and specificity 0.90 (95% CI: 0.87-0.93). For contrast-enhanced MRI (69 studies), pooled sensitivity was 0.93 (95% CI: 0.91-0.95) and specificity 0.89 (95% CI: 0.86-0.91). However, whether dynamic contrast-enhanced (DCE) was performed during MRI diagnosis of benign and malignant ovarian tumors had little effect on the pooled sensitivity, while the pooled specificity of studies that performed DCE might be slightly higher than those that did not.

conclusionsMRI plays a crucial role in differentiating between benign and malignant ovarian tumors, and DWI can serve as an auxiliary diagnostic tool, used concurrently with conventional MRI, while the diagnostic efficacy of DCE and non-DCE is similar. Prospective studies using MRI scoring systems and sample sizes exceeding 100 also show better diagnostic performance.

Indexed as

Magnetic Resonance ImagingOvarian NeoplasmsDiagnosis, DifferentialFemaleHumansSensitivity and SpecificityAdnexal massesDiffusion-weighted imagingMagnetic resonance imagingMR; DWIOvarian cancerOvarian massesOvarian tumor

Identifiers

PMID42118277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.